Neurocrine Bioscienc (NBIX) 50.23 $NBIX Neurocrine

New Post Public Reply Private Reply Replies (0) Message Board

Aug 1, 2016 at 12:07 AM

Neurocrine Bioscienc (NBIX) 50.23 $NBIX

Neurocrine Announces Initiation of a Long-Term Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Tourette Syndrome
PR Newswire - Thu Jul 28, 3:02PM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase II clinical trial for NBI-98854 (valbenazine), a highly selective small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, in children, adolescents and adults with Tourette syndrome.
NBIX: 50.23 (+0.08)

Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2016 Results
PR Newswire - Wed Jul 27, 12:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its second quarter 2016 results after the Nasdaq market closes on Wednesday, August 3, 2016. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Wednesday afternoon, August 3, 2016 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
NBIX: 50.23 (+0.08)

Look for Shares of Neurocrine Biosciences to Potentially Rebound after Yesterday's 2.85% Sell Off
Comtex SmarTrend(R) - Wed Jul 13, 1:23PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $46.31 to a high of $48.70. Yesterday, the shares fell 2.9%, which took the trading range below the 3-day low of $47.06 on volume of 391,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NBIX: 50.23 (+0.08)

Essential Tremor Pipeline Review 2016 Featuring Merz GmbH & Co., Neurocrine Biosciences & Sage Therapeutics - Research and Markets
BusinessWire - Thu Jul 07, 11:08AM CDT
Research and Markets has announced the addition of the "Essential Tremor - Pipeline Review, H1 2016" report to their offering.
NBIX: 50.23 (+0.08)

Notable Thursday Option Activity: NBIX, RAD, SEAS
DividendChannel.com - Thu Jun 23, 2:29PM CDT
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Neurocrine Biosciences, Inc. , where a total of 4,984 contracts have traded so far, representing approximately 498,400 underlying shares.
NBIX: 50.23 (+0.08)

Watch for Neurocrine Biosciences to Potentially Rebound After Falling 4.83% Yesterday
Comtex SmarTrend(R) - Tue Jun 21, 3:42PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $41.70 to a high of $44.86. Yesterday, the shares fell 4.8%, which took the trading range below the 3-day low of $44.04 on volume of 786,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NBIX: 50.23 (+0.08)

Neurocrine Biosciences to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Thu Jun 02, 2:45PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Jefferies 2016 Healthcare Conference in New York City.
NBIX: 50.23 (+0.08)

nLife Therapeutics appoints Dr. Errol B. De Souza as Executive Chairman
GlobeNewswire - Wed Jun 01, 4:11AM CDT
nLife Therapeutics, an early-stage biopharmaceutical company leading developments in conjugated nucleic acids as therapeutic agents for central nervous system (CNS) and neuromuscular (NS) disorders, today announced the appointment of Dr. Errol B. De Souza, Ph.D. as executive chairman.
NBIX: 50.23 (+0.08), TRGT: 0.96 (-1.25), CBIO: 1.49 (unch), PTN: 0.81 (+0.01), IDXX: 93.79 (+0.58), BIOD: 0.44 (-0.01)

Neurocrine Biosciences Rises 8.70% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue May 31, 2:08PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $48.49 to a high of $50.87. Yesterday, the shares gained 8.7%, which took the trading range above the 3-day high of $49.44 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NBIX: 50.23 (+0.08)

Neurocrine Biosciences Falls 3.33% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu May 26, 2:35PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $44.41 to a high of $46.47. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $46.01 on volume of 513,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NBIX: 50.23 (+0.08)

Neurocrine Biosciences Announces the Retirement of W. Thomas Mitchell from the Board of Directors
PR Newswire - Fri May 20, 8:00AM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that W. Thomas Mitchell has notified the Company that he is retiring from the Board of Directors effective just prior to the 2016 Annual Meeting of Shareholders. Mr. Mitchell has been a member of the Board of Directors for over thirteen years serving in various capacities on the audit, compensation, and nominating and corporate governance committees.
NBIX: 50.23 (+0.08)

After Yesterday's Rally of 4.19% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon May 16, 4:19PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $43.79 to a high of $46.11. Yesterday, the shares gained 4.2%, which took the trading range above the 3-day high of $44.60 on volume of 434,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NBIX: 50.23 (+0.08)

Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
PR Newswire - Fri May 06, 2:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas.
NBIX: 50.23 (+0.08)

Neurocrine Biosciences Announces Additional Valbenazine (NBI-98854) Data to be Presented at the American Psychiatric Association's 2016 Annual Meeting in Atlanta
PR Newswire - Fri May 06, 7:30AM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that four abstracts representing additional data from both the Kinect 3 and Kinect 2 tardive dyskinesia clinical trials of valbenazine will be presented at the American Psychiatric Association Annual Meeting in May. The four posters will include an evaluation of the impact of valbenazine on the psychiatric stability of subjects with underlying schizophrenia, schizoaffective disorder or mood disorder (including bipolar disorder or major depressive disorder), data assessing the effect of valbenazine stratified by baseline tardive dyskinesia severity, and an evaluation of valbenazine with concomitant antipsychotic use. The APA Annual Meeting is the largest international conference of psychiatrists and behavioral health specialists, bringing together an estimated 13,000 clinicians and scientists to address current topics in psychiatry.
NBIX: 50.23 (+0.08)

Neurocrine reports 1Q loss
Automated Insights - Thu May 05, 5:22PM CDT
SAN DIEGO (AP) _ Neurocrine Biosciences Inc. (NBIX) on Thursday reported a loss of $19.3 million in its first quarter.
NBIX: 50.23 (+0.08)

Neurocrine Biosciences Reports First Quarter 2016 Results
PR Newswire - Thu May 05, 3:01PM CDT
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended March 31, 2016. For the first quarter of 2016, the Company reported a net loss of $19.3 million, or $0.22 loss per share, compared to a net loss of $1.2 million, or $0.01 loss per share, for the same period in 2015.
NBIX: 50.23 (+0.08)

Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2016 Results
PR Newswire - Fri Apr 29, 2:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2016 results after the Nasdaq market closes on Thursday, May 5, 2016. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Thursday afternoon, May 5, 2016 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
NBIX: 50.23 (+0.08)

Neurocrine Biosciences to Present at the Deutsche Bank 41st Annual Health Care Conference
PR Newswire - Wed Apr 27, 2:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Deutsche Bank 41st Annual Health Care Conference in Boston.
NBIX: 50.23 (+0.08), DB: 13.44 (+0.19)

Shares of NBIX Up 23.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Apr 22, 1:24PM CDT
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on March 31st, 2016 at $38.80. In approximately 3 weeks, Neurocrine Biosciences has returned 23.50% as of today's recent price of $47.91.
NBIX: 50.23 (+0.08)

Watch for Neurocrine Biosciences to Potentially Pullback After Gaining 5.66% Yesterday
Comtex SmarTrend(R) - Mon Apr 04, 4:03PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $42.00 to a high of $44.30. Yesterday, the shares gained 5.7%, which took the trading range above the 3-day high of $41.68 on volume of 756,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NBIX: 50.23 (+0.08)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

OmniActive's Fenavari: A New Era in Women's Health

Pioneering Women's Health with Fenavari You ever wonder why some health products get all the hype? Here's one for the book: OmniActive Health Technologies launching Fenavari, their top-tier contender in the women's health market. Now, we're not talking your run-of-the-mill supplement here. We're stepping onto a new playing field, especially with Dr. Taz Bhatia stepping...

Celebree Gains Franchise Momentum: A New Frontier

The Climb: Celebree Schools on the Rise Here's a nugget in the franchise world that's causing a stir: Celebree School is making moves up the Franchise Times Top 400. When we're talking about a hop, skip, and jump through 84 spots since 2023, you can't help but notice. It's the third year in a row they're climbing this ladder, and it's making ripples. Franchise Expansion...

Trial for Former OB/GYN Arthur Park Begins in Bakersfield

A Somber Day for Justice in Bakersfield There’s a buzz in the air, thick with anticipation and grief, as a trial seven years in the making kicks off in Bakersfield. It’s a significant affair, marking a turning point in a saga that’s shadowed the region with untold grief and unresolved accountability. We’re talking about the trial of Arthur Park, a former OB/GYN,...

Montessori and Tech: A New Era of Integration

Reimagining Montessori with Technology Let's take a stroll down the road less traveled—the intersection of Montessori education and tech. For over a century, Montessori schools have valued individual child development, autonomy, and a purpose-driven environment. But let's face it, their technology hasn't always had the same handcrafted finesse. That's where illumine...

New American Funding Expands in Carolinas with Mullinix Move

The Gathering of Mortgage Titans You don't just waltz into the mortgage world with a $2 billion track record and expect folks not to notice. Will Mullinix, a name that's become synonymous in the Carolinas with mortgage mastery, has decided to bring his influential Mullinix Mortgage Group under the banner of New American Funding. Talk about a power play. This bold strategy...

Simple Home Upgrades That Boost Value Fast

Transform Your Home's Curb Appeal Without Breaking The Bank Every homeowner knows that feeling when you look at your house one day and think, "This could use a little something." Say you're strolling through a neighborhood in Fulton, N.Y., and notice a gem. It's not a brand new build, but it gleams with character. You bet it's had a few smart touches that could apply...

Partner Valuation Advisors Bolsters Team with Eichman

Eichman Joins Partner Valuation Advisors as MD Turns out the buzz in real estate appraisal isn’t just about property values these days; it's about who's valuing them. Just ask Partner Valuation Advisors, who are realigning their chess pieces by bringing seasoned pro Justin Eichman, MAI, on board as Managing Director. Talk about playing your cards right. A Heavyweight in...

Skiptown Expands in Georgia Amid Growing Demand

With the pet care industry barking up a storm lately, Skiptown is ramping up efforts to expand its presence in Georgia. The tech-enabled dog care franchise already has a paw print in Atlanta, but it's sniffing out new opportunities across the state. Now they're on the hunt for franchise owners who can bring this modern approach to more communities. Why Georgia? The Growth...

Veterans Transitioning to Real Estate with Scholarships

Tapping Military Skills for Civilian Gain Finding a new career after military service is a mountain of a task, but veterans now have a golden ticket into the real estate appraisal world. The Appraisal Institute's Next Mission Scholarship is throwing veterans a $1,000 life preserver to dive into a field where their military-honed skills already shine. The Power of a...

Dr. Anderson’s Journey: Leadership with Faith and Service

A Life Shaped by Service Dr. Howard Anderson isn't just another name in a glossy award roster—he's a powerhouse of leadership, a chaplain of compassion, and a soldier in spirit. Honored as a Pinnacle Professional Member of The Inner Circle of Excellence, his recognition feels less like an accolade and more like a testament to a life committed to serving others. The...